Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 165 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The firm's research focuses on signaling pathways that are critical to disease mechanisms. The firm's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 165 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The firm's research focuses on signaling pathways that are critical to disease mechanisms. The firm's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).
Revenue: Rigel reported fourth-quarter total revenue of $69.8 million and record net product sales of $65.4 million, up 41% year-over-year.
Profitability: The company reported net income of $268.1 million in Q4 driven largely by a $245.9 million noncash deferred tax benefit and is profitable for the full year with net income of $367 million.
Commercial momentum: Full-year 2025 net product sales were $232 million, up $87 million or 60% vs. 2024, driven by TAVALISSE, REZLIDHIA and GAVRETO.
R289 progress: Phase Ib dose-escalation data in relapsed/refractory lower-risk MDS showed RBC transfusion independence (RBC-TI) in 6 of 18 evaluable patients (33%) at doses ≥500 mg, median duration ~23 weeks; dose-expansion data and recommended Phase II dose decision expected in second half of 2026 with top-line expansion data by year-end.
Guidance: 2026 total revenue guidance of approximately $275 million to $290 million, including net product sales of approximately $255 million to $265 million and contract revenues of $20 million to $25 million; company expects positive net income for the year.
Business development: Management reiterated focus on late-stage in-licensing/acquisitions in hematology/oncology to leverage commercial infrastructure; actively evaluating opportunities but timing uncertain.
Capital position: Cash, cash equivalents and short-term investments ended 2025 at $155 million, up from $77.3 million at year-end 2024.
